<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5614-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LATUDA 20 MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LURASIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        243.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Bushu Pharmaceuticals Ltd. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Bushu Pharmaceuticals Ltd. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Medius AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AE05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Latuda contains the active substance lurasidone hydrochloride and is prescribed by your doctor for the treatment of the following disease:</p><p>Latuda is used for the treatment of schizophrenia in adults aged 18&nbsp;years or over. Schizophrenia, an illness that is classified as a psychosis. Schizophrenia is a disorder of brain function that affects cognition, perception and/or behaviour. Typical symptoms include confusion, hallucinations, distorted perception (e.g. hearing the voice of a person who is not present), delusions, social alienation and excessive introversion as well as anxiety and tension.</p><p>Latuda is also used, alone or in combination with lithium or valproate, in adults for the treatment of depressive episodes associated with bipolar disorder. Typical symptoms may include: sadness, loss of interest, joylessness, lack of energy, change in appetite, sleep disorders, difficulty concentrating.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>When you should not take Latuda</p><p>You should not take Latuda if you have a known hypersensitivity to the active substance lurasidone hydrochloride or to one of the excipients. Hypersensitivity can manifest itself, for example, as skin rash, which may be itchy and include swelling, blistering or red patches on the skin, shortness of breath or swollen face. If you notice any such symptoms, notify your doctor immediately.</p><p>Tell your doctor beforehand if you have to take other medicines. Some medicines may affect the metabolism of Latuda &ndash; mainly anti-infective drugs, e.g. products containing the active substances ketoconazole or rifampicin. These should not be taken with Latuda, as they could result in concentrations of the medicine in the body that are much higher or lower than desired.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Latuda is not indicated for the treatment of psychiatric problems in patients with dementia (including Alzheimer&rsquo;s disease).</p><p>Tell your doctor if you currently have or have had any of the following conditions in the past.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney or liver impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High cholesterol or blood lipid levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being overweight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hormone-dependent tumour</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Drug-induced) deficiency of white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiovascular diseases accompanied by low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures</p><p>You should also inform your doctor if you have to take anticholinergic drugs (e.g. L-dopa, a medicine for the treatment of Parkinson&rsquo;s disease).</p><p>Consult your doctor immediately if one or more of the following symptoms occur during treatment with Latuda:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden change in mental state</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure, malaise after standing up suddenly e.g. nausea, dizziness or fainting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness on one side of the body or numbness of the face, arms and legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Speech or vision disturbances</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extreme fever (&gt; 41&deg;C), muscular rigidity (These can be signs of severe malignant neuroleptic syndrome, which requires immediate medical attention.)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular pulse and racing heart</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Profuse sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discoloured urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Involuntary or disturbed movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Susceptibility to infections or unexplained infections or high fever (This may be due to a reduction in the white blood cell count and requires immediate medical clarification.)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High body temperature due to strenuous exercise, excessive heat exposure and dehydration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suicidal thoughts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough, shortness of breath or difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious blistering rash affecting the skin, mouth, eyes and genitals (called Stevens-Johnson syndrome) may occur, the frequency of occurrence is not known. This rash may be itchy and include swelling, blistering or red patches on the skin.</p><p>Tell your doctor if you experienced such undesirable effects in the past while taking antipsychotic drugs.</p><p>Tell your doctor or pharmacist if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have other illnesses</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have allergies or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking or externally applying other medicines (including medicines bought over the counter). In particular, this includes medicines for the treatment of Parkinson&rsquo;s disease, weak bladder, cramp-like pain or high blood pressure.</p><p>&nbsp;</p><p><strong><em>Children and adolescents </em></strong></p><p>This medicine is not recommended for children and adolescents under 18&nbsp;years .The use and safety of Latuda in children and adolescents have not been studied to date.</p><p>&nbsp;</p><p><strong><em>Latuda </em></strong><strong><em>with food, drink and alcohol</em></strong></p><p>Caution is advised when using Latuda in combination with alcohol.</p><p>Do not drink grapefruit juice while taking Latuda. Grapefruit juice can affect the efficacy of the medicine.</p><p>Use of Latuda during pregnancy and breast-feeding</p><p>No controlled studies are available on the use of Latuda during pregnancy and breast-feeding. Latuda should therefore not be used during pregnancy unless prescribed by your doctor. You should therefore talk to your doctor before treatment with Latuda if you are pregnant, are planning to become pregnant or are breast-feeding.</p><p>&nbsp;</p><p><strong><em>Driving and using machines </em></strong></p><p>This medicine can affect reactions, the ability to drive and the ability to use tools or machines. Therefore, caution is required when using dangerous machines, including motorised vehicles, until you have reasonably assessed your reactions and consulted your doctor, and can be sure that treatment with Latuda has no unfavourable effects on you.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will determine the appropriate dose for you. It is very important that you take Latuda as it has been prescribed for you.</p><p>For the treatment of schizophrenia, the recommended initial dose is one 40&nbsp;mg film-coated tablet once daily.</p><p>For the treatment of depression associated with bipolar disorder in adults, the recommended initial dose is one 20&nbsp;mg film-coated tablet once daily.</p><p>Your doctor can increase the dose if necessary. It is recommended that the dose be adjusted in patients with moderate or severe kidney or liver impairment.</p><p>It is best to always take Latuda at the same time of day, e.g. at noon, with a meal (at least 350 calories).</p><p>This medicine is not recommended for children and adolescents under 18&nbsp;years. The use and safety of Latuda in children and adolescents have not been studied to date.</p><p><strong><em>If you take more Latuda than you should</em></strong></p><p>If you take more than the prescribed dose, notify your doctor or pharmacist immediately.</p><p><strong><em>If you forget to take </em></strong><strong><em>Latuda</em></strong></p><p>If you forget to take Latuda, make up for the forgotten dose as soon as you remember, unless you are already due to take the next dose. In that case, you should omit the forgotten dose and take the next dose as scheduled. Continue the treatment as planned. Do not take a double dose to make up for a forgotten dose.</p><p>Do not change the prescribed dose. If you think the medicine is too weak or too strong, speak to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em><u>The following most common side effects may occur during use of Latuda</u></em>:</p><p>The most common side effects of Latuda in patients with schizophrenia are: sleepiness, akathisia (inability to remain sitting still), nausea, parkinsonism (feeling of stiffness, tremors at rest, dragging gait, expressionless face). Call your healthcare provider if you have any of these symptoms.</p><p>The most common side effects of Latuda in patients with bipolar depression are: akathisia (inability to remain sitting still), parkinsonism (feeling of stiffness, tremors at rest, dragging gait, expressionless face) and sleepiness. Call your healthcare provider if you have any of these symptoms.</p><p><em><u>The following side effects may also happen:</u></em></p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of restlessness and inability to sit still</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness.</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insomnia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbed control of muscular function, e.g. involuntary contraction of individual muscles (dystonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; racing heart</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased salivation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash and itching</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; panic attacks,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disorders,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicidal thoughts,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; completed suicide,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; attempted suicide,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary movements, mainly of the face or tongue (tardive dyskinesias),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; speech disturbances,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiac arrhythmias,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiac pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow pulse,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypotension, e.g. after standing up suddenly, or even fainting,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of consciousness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the gastric mucosa,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taste disorder,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsion,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision impairment,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tinnitus,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased reflux of acid stomach contents into the gullet,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tongue disease,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erectile dysfunction,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary incontinence,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritability,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver diseases,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty and/or pain while urinating,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; absence of the menses and menstruation problems,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low sodium levels in the blood, which can cause fatigue, and confusion,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle twitching, seizure and coma (hyponatraemia).</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden death,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced white blood cell counts (which can lead to infections),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepwalking,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; malignant neuroleptic syndrome (extreme fever with muscular rigidity),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle wasting,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of superficial veins,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the skin and mucous membranes,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast enlargement and pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nipple discharge,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aspiration pneumonia (inflammation of the lungs caused by breathing in foreign matter or fluid) and symptoms such as throat swelling may occur.</p><p>If you experience any other side effects that are not described here, talk to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the container after &laquo;EXP&raquo;.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environmentIf you need further information, talk to your doctor or pharmacist, who will have the comprehensive summary of product characteristics.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is lurasidone hydrochloride.</p><p>Each 20&nbsp;mg film‑coated tablet contains 20&nbsp;mg lurasidone hydrochloride equivalent to 18.6 mg lurasidone.</p><p>Each 40&nbsp;mg film‑coated tablet contains 40&nbsp;mg lurasidone hydrochloride equivalent to 37.2 mg lurasidone.</p><p>Each 80mg film‑coated tablet contains 80mg lurasidone hydrochloride equivalent to 74.5 mg lurasidone</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are mannitol, pregelatinised starch, croscarmellose sodium, hypromellose, magnesium stearate (E470b), titanium dioxide (E171), macrogol, yellow iron oxide (E172) (present in 80&nbsp;mg tablets), indigotine (E132) (present in 80&nbsp;mg tablets) and carnauba wax (E903).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Latuda 20 mg film coated tablets are white to off white, round film coated tablets debossed “L 20”
•	Latuda 40 mg film coated tablets are white to off white, round film coated tablets debossed with “L 40”
•	Latuda 80 mg film coated tablets are pale green, oval film coated tablets debossed with “L 80”.

Latuda film coated tablets are available in pack sizes containing 28 film coated tablet in aluminium/aluminium perforated unit dose blisters (2 blister strips, each containing 14 film coated tablets).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing authorisation holder</p><p>Medius AG, Neue Bahnhofstrasse 160, 4132 Muttenz, Basel, Switzerland</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Bulk Manufacturer</em></strong></p><p>Bushu Pharmaceuticals Ltd.</p><p>1 Takeno, Kawagoe, Saitama, 350-0801</p><p>Japan</p><p><em>&nbsp;</em></p><p><strong><em>Batch Releaser</em></strong></p><p>AndersonBrecon (UK) Ltd.</p><p>Units 2-7</p><p>Wye Valley Business Park</p><p>Brecon Road</p><p>Hay-on-Wye</p><p>Hereford</p><p>HR3 5PG</p><p>United Kingdom</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2019 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواء لاتودا على المادة الفعَّالة لوراسيدون هيدروكلوريد ويتم وصفه من قبل الطبيب لعلاج المرض الآتي:</p><p dir="RTL">يُستخدم دواء لاتودا لعلاج الفُصَام لدى البالغين ممن تبلغ أعمارهم 18 سنة فأكثر،وهو مرض يُصنف على أنه إحدى الحالات الذهانية. الفُصَام هو أحد اضطرابات وظائف المخ التي تُؤثر على المعرفة، الإدراك و/ أو السلوك. تشمل الأعراض النمطية الارتباك/الالتباس، الهلاوس، خلل في الادراك (على سبيل المثال: سماع صوت شخص غير موجود)، الأوهام، العزلة الاجتماعية والانطواء المُفرط بالإضافة إلى القلق والتوتر.</p><p dir="RTL">يُستخدم دواء لاتودا أيضًا بمفرده أو بمصاحبة الليثيوم أو فالبروات في البالغين لعلاج نوبات الاكتئاب المُصاحبة للاضْطِّراب ثنائي القطب. قد تشمل الأعراض النمطية: الحزن، فقدان الاهتمام، التعاسة، نقص الطاقة، طروء تغيير على الشهية، اضطرابات بالنوم، صعوبة التركيز.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p>متى ينبغي عليك عدم تَناوُل دواء لاتودا</p><p dir="RTL">ينبغي ألا تتناول دواء لاتودا إذا كنت تعاني من<strong><em> </em></strong>إحدى حالات فرط الحساسية المعروفة تجاه المادة الفعّالة لوراسيدون هيدروكلوريد &nbsp;أو تجاه أحد السواغات (المواد غير الفعَّالة). يمكن لفرط الحساسية أن يظهر من تلقاء نفسه ، على سبيل المثال: على هيئة طفح جلدي ربما يكون مثيرًا للحكة ويتضمن حدوث تورم أو ظهور تقرحات &nbsp;أو بقع حمراء على الجلد أو ضيق بالتَّنفس أو تورم بالوجه. أبلغ طبيبك على الفور إذا لاحظت أيًّا من هذه الأعراض.</p><p dir="RTL">أخبر طبيبك مُسبقًا إذا كان يتعين عليك تناوُل أدوية أخرى. قد تُؤثر بعض الأدوية على استقلاب دواء لاتودا &ndash; المضادات الحيوية بشكل أساسي، على سبيل المثال: المنتجات التي تحتوي على المادتين الفعالتين كيتوكونازول أو ريفامبيسين. ينبغي ألا يتم تناوُل تلك الادوية بمصاحبة دواء لاتودا فقد تتسبب في ارتفاع أو انخفاض تركيزات الدَّواء في الجسم عما هو مرغوب.</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">لا يُستخدَم دواء لاتودا لعلاج المشاكل النفسية في المرضى المُصابين بالخرف (بما في ذلك مرض آلزهايمر).أخبر طبيبك إذا كنت تعاني حاليًا أو قد عانيت سابقًا من أي من الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القصور الكُلوي أو الكبدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السُّكَّرِي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات الكوليسترول أو الدهون بالدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأورام التي تعتمد على الهرمونات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم البيضاء (بسبب دواء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض القلب والأوعية الدَّموية المصحوبة بانخفاض ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات تشنجية.</p><p dir="RTL">ينبغي عليك أيضًا إبلاغ طبيبك إذا كان يتعين عليك تناوُل الأدوية المضادة للكولين (على سبيل المثال: ليفودوبا، وهو أحد الأدوية التي تُستخدم لعلاج مرض الشلل الرعَّاش (مرض باركنسون)).</p><p dir="RTL">استشر طبيبك فورًا إذا حدث واحد أو أكثر من الأعراض التَّالية أثناء الخضوع للعلاج بدواء لاتودا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير مفاجئ في الحالة العقلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم, تَوَعُّك بعد النهوض فجأة على سبيل المثال: غثيان، دوخة أو إغماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف بأحد جانبي الجسم أو تنميل الوجه، الذراعين والساقين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالكلام أو الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمّى شديدة (&gt; 41 درجة مئوية)، تصلب عضلي (هذان العرضان قد يكونان علامتين على الإصابة بمتلازمة الذهان الخبيثة ، والتي تتطلب عناية طبية فورية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام النبض وتسارع ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرُّق بغزارة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير إرادية أو مُضطربة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القابيلة للإصابة بالعدوى أو الإصابة بعدوى غير مُبررة أو حُمى مرتفعة (قد يكون ذلك نتيجة انخفاض عدد خلايا الدَّم البيضاء ويتطلب ذلك توضيحًا طبيًّا فوريًّا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة حرارة الجسم نتيجة ممارسة التَّمارين الشَّاقة، التَّعرض المفرط للحرارة والجفاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار انتحارية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُعال، ضيق التنفس أو صعوبة التَّنفُّس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث طفح جلدي خطير يكون مصحوبًا بتقرحات &nbsp;ويُؤثر على الجلد والفم والعينين والأعضاء التَّناسلية (يُسمى متلازمة ستيفنز جونسون)، ومعدل تكرار الحدوث غير معروف. ربما يكون الطفح الجلدي هذا مثيرًا للحكة ويتضمن حدوث تورم أو ظهورتقرحات أو بقع حمراء على الجلد.</p><p dir="RTL">أخبر طبيبك إذا عانيت سابقًا من مثل هذه الآثار غير المرغوبة أثناء تناوُل مضادات الفصام .</p><p dir="RTL">أخبر طبيبك أو الصيدلي الخاص بك في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أدوية أخرى أو كنت تستخدمها استخدامًا خارجيًّا (بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية). يشمل ذلك على وجه الخصوص الأدوية التي تُستخدَم لعلاج مرض الشلل الرعَّاش (مرض باركنسون)، ضعف المثانة، الآلام الشبيهة بالتقلصات أو ارتفاع ضغط الدَّم.</p><p dir="RTL"><strong><em>الأطفال والمراهقون </em></strong></p><p dir="RTL">لا ينصح باستخدام هذا الدَّواء للأطفال والمراهقين أقل من 18 عامًا .لم تتم حتى الآن دراسة استخدام دواء لاتودا وأمانه في الأطفال والمراهقين.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong><em>تناوُل دواء لاتودا </em></strong><strong><em>مع الأطعمة والمشروبات والكحوليات</em></strong></p><p dir="RTL">يُنصح بتوخي الحذر عند استخدام دواء لاتودا بمصاحبة المشروبات الكحولية</p><p dir="RTL">لا تشرب عصير الجريب فروت أثناء تناوُل عقار لاتودا. قد يُؤثر عصير الجريب فروت على فعَّالية الدَّواء.</p><p dir="RTL">&nbsp;</p><p>استخدام دواء لاتودا أثناء الحمل والرضاعة الطبيعية</p><p dir="RTL">لا تتوافر أية دراسات مُضبطة حول استخدام دواء لاتودا أثناء الحمل والرضاعة الطبيعية. لذا، لا يجب استخدام دواء لاتودا أثناء فترة الحمل ما لم يتم وصفه من قبل طبيبكِ. لذلك ينبغي عليكِ التَّحدث إلى طبيبكِ قبل الخضوع للعلاج بدواء لاتودا إذا كنتِ حاملًا أو كنتِ تعتزمين الحمل أو كنتِ تمارسين الرضاعة الطبيعيَّة.</p><p dir="RTL"><strong><em>القيادة واستخدام الآلات</em></strong></p><p dir="RTL">قد يُؤثر هذا الدَّواء على ردود الأفعال، القدرة على ممارسة القيادة والقدرة على استخدام الأدوات أو الآلات. لذلك، يجب توخي الحذر عند استخدام الآلات الخطيرة، بما في ذلك المركبات الآلية، إلى أن تقيم ردود أفعالك بشكل معقول وتستشر طبيبك وتتأكد من أن العلاج بدواء لاتودا ليس له أية تأثيرات غير مرغوبة عليك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيحدد طبيبك الجرعة المناسبة لك. من المهم جدًّا أن تتناول دواء لاتودا على النحو الذي تم وصفه لك.</p><p dir="RTL">لعلاج الفُصَام، تبلغ الجرعة الأولية المُوصى بها قرصًا واحدًا مُغلَّفًا 40 مجم مرَّة واحدة يوميًّا.</p><p dir="RTL">لعلاج الاكتئاب المصاحب للاضْطِّراب ثنائي القطب في البالغين، تبلغ الجرعة الأولية المُوصى بها قرصًا واحدًا مُغلَّفًا 20 مجم مرَّة واحدة يوميًّا.</p><p dir="RTL">يمكن لطبيبك أن يزيد الجرعة إذا لزم الأمر. يُوصى بأن يتم ضبط الجرعة في المرضى الذين يعانون من قصور كُلوي أو كبدي معتدل أو شديد.</p><p dir="RTL">يُفضل دائمًا تناوُل دواء لاتودا في الوقت نفسه من اليوم، على سبيل المثال ظهرًا، مع تناوُل إحدى الوجبات (350 سعرًا حراريًّا على الأقل).</p><p dir="RTL">لا ينصح باستخدام هذا الدَّواء للأطفال والمراهقين أقل من 18 عامًا .لم تتم حتى الآن دراسة استخدام دواء لاتودا وأمانه في الأطفال والمراهقين.</p><p dir="RTL"><strong><em>إذا تناولت كمية أكثر مما يجب من دواء لاتودا</em></strong></p><p dir="RTL">&nbsp;أبلغ طبيبك أو الصيدلي الخاص بك فورًا إذا تناولت جرعة أكبر من تلك التي تم وصفها لك.</p><p dir="RTL"><strong><em>إذا أغفلت تناوُل دواء لاتودا</em></strong></p><p dir="RTL">إذا أغفلت تناوُل دواء لاتودا قم بتعويض الجرعة التي أغفلتها بمجرد أن تتذكر ما لم يكن موعد تناوُل الجرعة التَّالية قد حان بالفعل. في تلك الحالة، ينبغي عليك تجاهل الجرعة التي أغفلتها وتناوُل الجرعة التَّالية على النحو المُقرر. واصل العلاج على النحو المُخطط له. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">لا تغير الجرعة الموصوفة لك. إذا شعرت أن الدَّواء أقوى من اللازم أو أقل من اللازم، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL"><em><u>الآثار الجانبية التالية هي الأكثر شيوعًا &nbsp;&nbsp;وقد تحدث أثناء استخدام دواء لاتودا</u></em><em><u>:</u></em></p><p dir="RTL">الآثار الجانبية الأكثر شيوعًا لدواء لاتودا في المرضى الذين يعانون من الفُصَام هي: النعاس، اكاثيسيا (عدم القدرة على الجلوس ساكنًا)، الغثيان، البَاَرْكِنْسُونِيَّة (الشعور بالتصلب، الارتعاش عند الاسترخاء، المشي بجر القدمين، وجه خالٍ من التَّعْبِيرات). تحدث مع مقدم الرعاية الصحية الخاص بك إذا كان لديك أي من هذه الأعراض.</p><p dir="RTL">الآثار الجانبية الأكثر شيوعًا لدواء لاتودا في المرضى الذين يعانون من الاكتئاب ثنائي القطب هي: اكاثيسيا (عدم القدرة على الجلوس ساكنًا)، البَاَرْكِنْسُونِيَّة (الشعور بالتصلب، الارتعاش عند الاسترخاء، المشي بجر القدمين، وجه خالٍ من التَّعْبِيرات) والنعاس. تحدث مع مقدم الرعاية الصحية الخاص بك إذا كان لديك أي من هذه الأعراض.</p><p dir="RTL"><em><u>قد تحدث الآثار الجانبية التالية أيضًا</u></em><em>:</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا (قد تؤثر في أكثر من </strong><strong>1</strong><strong> من كل </strong><strong>10</strong><strong>&nbsp;أشخاص):</strong></p><ul><li dir="RTL">الشعور بعدم ارتياح وعدم القدرة على الجلوس ساكنًا</li><li dir="RTL">النعاس</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>10</strong><strong>&nbsp;أشخاص):</strong></p><ul><li dir="RTL">القلق</li><li dir="RTL">الأَرَق</li><li dir="RTL">الشعور بعدم ارتياح</li><li dir="RTL">الاكتئاب</li><li dir="RTL">الدوخة</li><li dir="RTL">اضطراب التحكم بالوظائف العضلية، على سبيل المثال: تقلص العضلات الفردية بشكل غير إرادي (خلل التوتر)</li><li dir="RTL">&nbsp;آلام الظهر</li><li dir="RTL">تسارع ضربات القلب</li><li dir="RTL">ارتفاع ضغط الدم</li><li dir="RTL">&nbsp;ألم بالبطن</li><li dir="RTL">الإسهال</li><li dir="RTL">&nbsp;ألم بالجزء العلوي من البطن</li><li dir="RTL">&nbsp;القيء</li><li dir="RTL">&nbsp;زيادة سيلان اللعاب</li><li dir="RTL">الإمساك</li><li dir="RTL">&nbsp;جفاف الفَم</li><li dir="RTL">عدم وضوح الرؤية</li><li dir="RTL">&nbsp;انخفاض الشهية</li><li dir="RTL">&nbsp;الحمى</li><li dir="RTL">&nbsp;أعراض نزلة البرد</li><li dir="RTL">&nbsp;عدوى المسالك البولية</li><li dir="RTL">&nbsp;الطفح الجلدي والحكة</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>100</strong><strong> شخص):</strong></p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">فقر الدَّم،</li><li dir="RTL">الأحلام غير الطبيعية،</li><li dir="RTL">نوبات الهلع،</li><li dir="RTL">اضطرابات بالنوم،</li><li dir="RTL">الأفكار الانتحارية،</li><li dir="RTL">الانتحار،</li><li dir="RTL">الإقدام على الانتحار،</li><li dir="RTL">الحركات غير الإرادية غالبا بالوجه أو اللسان (خَلل الحَرَكَة المُتَأخِّر)،</li><li dir="RTL">السكتة الدماغية،</li><li dir="RTL">اضطرابات في الكلام،</li><li dir="RTL">الدوار،</li><li dir="RTL">اضطرابات النظم القلبي،</li><li dir="RTL">ألم بالقلب،</li><li dir="RTL">تباطؤ النبض،</li><li dir="RTL">انخفاض ضغط الدَّم، على سبيل المثال: بعد النهوض فجأة، أو حتى الإغماء،</li><li dir="RTL">الهبَّات الساخنة،</li><li dir="RTL">فقدان الوعي،</li><li dir="RTL">التهاب الغشاء المخاطي في المعدة،</li><li dir="RTL">صعوبة البلع،</li><li dir="RTL">اضطراب بحاسة التَّذوق،</li><li dir="RTL">التشنج،</li><li dir="RTL">قصور بالرؤية،</li><li dir="RTL">طنين بالأذن،</li><li dir="RTL">زيادة ارتجاع حمض المعدة إلى المَرِيء</li><li dir="RTL">مرض باللسان،</li><li dir="RTL">التعرق المفرط،</li><li dir="RTL">الشرى (أرتكاريا)،</li><li dir="RTL">اضطرابات بالانتصاب،</li><li dir="RTL">سَلَسُ البَول،</li><li dir="RTL">عُسْرُ التَّنَفُّس،</li><li dir="RTL">الضعف،</li><li dir="RTL">الهياج،</li><li dir="RTL">أمراض الكبد،</li><li dir="RTL">صعوبة في التبول و/ أو ألم أثناء التبول،</li><li dir="RTL">انقطاع الحيض ومشاكل بالطمث،</li><li dir="RTL">انخفاض مستويات الصوديوم بالدَّم، مما قد يتسبب في إرهاق وارتباك/ التباس،</li><li dir="RTL">انتفاض عضلي، نوبة تشنجية وغيبوية (نَقْص الصوديوم بالدَّم).</li></ul><p dir="RTL"><strong>نادرة (في ما يصل إلى شخص واحد من بين كل </strong><strong>1000</strong><strong> شخص):</strong></p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">الموت المفاجئ ،</li><li dir="RTL">فشل الكُلى،</li><li dir="RTL">انخفاض عدد خلايا الدَّم البيضاء (الذي قد يؤدي إلى الإصابة بالعدوى)،</li><li dir="RTL">السير أثناء النوم،</li><li dir="RTL">متلازمة &nbsp;الذهان الخبيثة (حُمّى شديدة مصحوبة بتصلب عضلي)،</li><li dir="RTL">الهُزال العضلي،</li><li dir="RTL">التهاب الأوردة السطحية،</li><li dir="RTL">تورم الجلد والأغشية المخاطية،</li><li dir="RTL">تَضخُّم وألم بالثدي،</li><li dir="RTL">خروج إفرازات من الحلمة،</li><li dir="RTL">الالتهاب الرئوي الشَّفْطِيّ (التهاب الرئتين النَّاجم عن استنشاق مادة أو سائل غريب) وقد تحدث أعراض مثل تورم الحَلْق.</li></ul><p dir="RTL">إذا عانيت من أية آثار جانبية أخرى غير مذكورة في هذه النَّشرة، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة بعد كلمة &laquo;EXP&raquo;.</p><p dir="RTL">لا تخزن الدواء في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">يخزن داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت بحاجة إلى معلومات إضافية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك، ممن سيكون لديهما موجزًا شاملًا لخصائص المنتج.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>المادة الفعّالة</em><em>:</em> لوراسيدون هيدروكلوريد.</p><p dir="RTL">كل قرص20 مجم يحتوي على20 مجم لوراسيدون هيدروكلوريد بما يُعادل 18.6 مجم لوراسيدون</p><p dir="RTL">كل قرص40 مجم يحتوي على40 مجم لوراسيدون هيدروكلوريد بما يُعادل 37.2 مجم لوراسيدون.</p><p dir="RTL">كل قرص80 مجم يحتوي على80 مجم لوراسيدون هيدروكلوريد بما يُعادل 74.5 مجم لوراسيدون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>السواغات </em><em>(المواد غير الفعَّالة)</em></p><p dir="RTL">مانيتول، نشا سابق التجلتن، كروسكارميلوز الصوديوم، هيبروميلوز، ستيرات الماغنسيوم (E470b)، ثاني أكسيد التيتانيوم (E171)، ماكروجول، أكسيد الحديد الأصفر (E172) (يوجد في الأقراص 80 مجم)، إنديجوتين (E132) (يوجد في الأقراص 80 مجم) وشمع كرنوبا (E903).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء لاتودا أقراص مغلفة 20 مجم عبارة عن أقراص مغلَّفة دائرية الشَّكل، ذات لون أبيض إلى عاجي، محفور عليها &nbsp;&ldquo;L 20&rdquo;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء لاتودا أقراص مغلفة 40 مجم عبارة عن أقراص مغلَّفة دائرية الشَّكل، ذات لون أبيض إلى عاجي، محفور عليها &nbsp;&ldquo;L 40&rdquo;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء لاتودا أقراص مغلفة 80 مجم عبارة عن أقراص مغلَّفة بيضاوية الشكل، ذات لون أخضر شاحب، محفور عليها &nbsp;&ldquo;L 80&rdquo;..</p><p dir="RTL">&nbsp;</p><p dir="RTL">دواء لاتودا أقراص مغلفة متوفر في عبوة تحتوي على28 &nbsp;قرصًا مغلفًا في شرائط ألمونيوم/ألمونيوم مثقوبة (شريطين ، يحتوى كل شريط على 14 قرصًا مغلفًا).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التَّسويق</p><p dir="RTL">Medius AG, Neue Bahnhofstrasse 160, 4132 Muttenz, Basel, Switzerland.</p><p><em>&nbsp;</em></p><p dir="RTL"><strong><em>جهة التَّصنيع</em></strong></p><p>Bushu Pharmaceuticals Ltd.</p><p>1 Takeno, Kawagoe, Saitama, 350-0801</p><p>Japan</p><p><em>&nbsp;</em></p><p dir="RTL"><strong><em>Batch Releaser</em></strong></p><p>AndersonBrecon (UK) Ltd.</p><p>Units 2-7</p><p>Wye Valley Business Park</p><p>Brecon Road</p><p>Hay-on-Wye</p><p>Hereford</p><p>HR3 5PG</p><p>United Kingdom</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            (2019/05)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Latuda 18.5 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains lurasidone hydrochloride equivalent to18.6 mg lurasidone. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Latuda 18.5 mg film-coated tablets: white to off-white, film-coated round tablets of 6 mm debossed with ‘LA’


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Latuda is indicated for the treatment of schizophrenia in adults aged 18 years and over.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The recommended starting dose of lurasidone is 37 mg once daily. No initial dose titration is required. It is effective in a dose range of 37 to 148 mg once daily. Dose increase should be based on physician judgement and observed clinical response. The maximum daily dose should not exceed 148 mg.</p><p>&nbsp;</p><p>Patients on doses higher than 111 mg once daily who discontinue their treatment for longer than</p><p>3 days should be restarted on 111 mg once daily and up-titrated to their optimal dose. For all other doses patients can be restarted on their previous dose without need for up-titration.</p><p>&nbsp;</p><p><em>Elderly people</em></p><p>Dosing recommendations for elderly patients with normal renal function (CrCl &ge; 80 ml/min) are the same as for adults with normal renal function. However, because elderly patients may have diminished renal function, dose adjustments may be required according to their renal function status (see &ldquo;Renal impairment&rdquo; below).</p><p>&nbsp;</p><p>Limited data are available in elderly people treated with higher doses of lurasidone. No data are available in elderly people treated with Latuda 148 mg. Caution should be exercised when treating patients &ge;65 years of age with higher doses of Latuda.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment of lurasidone is required in patients with mild renal impairment.</p><p>In patients with moderate (Creatinine Clearance (CrCl) &ge; 30 and &lt; 50 ml/min), severe renal impairment (CrCL &gt;15 and &lt; 30 ml/min) and End Stage Renal Disease (ESRD) patients</p><p>&nbsp;</p><p>(CrCl &lt; 15 ml/min), the recommended starting dose is 18.5 mg and the maximum dose should not exceed 74 mg once daily. Latuda should not be used in patients with ESRD unless the potential benefits outweigh the potential risks. If used in ESRD, clinical monitoring is advised.</p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>No dose adjustment of lurasidone is required in patients with mild hepatic impairment.</p><p>Dose adjustment is recommended in moderate (Child-Pugh Class B) and severe hepatic impairment</p><p>(Child-Pugh Class C) patients. The recommended starting dose is 18.5 mg. The maximum daily dose in moderate hepatic impairment patients should not exceed 74 mg and in severe hepatic impairment</p><p>patients should not exceed 37 mg once daily.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of lurasidone in children aged less than 18 years have not been established. Current available data are described in section 5.2, but no recommendation on a posology can be</p><p>made.</p><p>&nbsp;</p><p><em>D</em><em>ose adjustment due to interactions</em></p><p>A starting dose of 18.5 mg is recommended and the maximum dose of lurasidone should not exceed</p><p>74 mg once daily in combination with moderate CYP3A4 inhibitors. Dose adjustment of lurasidone may be necessary in combination with mild and moderate CYP3A4 inducers (see section 4.5). For strong CYP3A4 inhibitors and inducers see section 4.3.</p><p>&nbsp;</p><p><em>Switching between antipsychotic medicinal products</em></p><p>Due to different pharmacodynamic and pharmacokinetic profiles among antipsychotic medicinal products, supervision by a clinician is needed when switching to another antipsychotic product is considered medically appropriate.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Latuda film-coated tablets are for oral use, to be taken once daily together with a meal.</p><p>If taken without food, it is anticipated that lurasidone exposure will be significantly lower as compared to when taken with food (see section 5.2).</p><p>&nbsp;</p><p>Latuda tablets should be swallowed whole, in order to mask the bitter taste. Latuda tablets should be taken at the same time every day to aid compliance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
-	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Concomitant administration of strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, cobicistat, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole,
ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) and strong CYP3A4 inducers (e.g.
carbamazepine, phenobarbital, phenytoin, rifampicin, St John’s wort (Hypericum perforatum) (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take a few days to some weeks. Patients should be closely monitored during this period.</p><p>&nbsp;</p><p><u>Suicidality</u></p><p>The occurrence of suicidal behaviour is inherent in psychotic illnesses and in some cases has been reported early after initiation or switch of antipsychotic therapy. Close supervision of high-risk</p><p>patients should accompany antipsychotic therapy.</p><p>&nbsp;</p><p><u>Parkinson&rsquo;s disease</u></p><p>If prescribed to patients with Parkinson&rsquo;s disease, antipsychotic medicinal products may exacerbate the underlying parkinsonism symptoms. Physicians should therefore weigh the risks versus the benefits when prescribing Latuda to patients with Parkinson&rsquo;s disease.</p><p>&nbsp;</p><p><u>Extrapyramidal symptoms (EPS)</u></p><p>Medicinal products with dopamine receptor antagonistic properties have been associated with extrapyramidal adverse reactions including rigidity, tremors, mask-like face, dystonias, drooling of</p><p>saliva, drooped posture and abnormal gait. In placebo controlled clinical studies in adult patients with schizophrenia there was an increased occurrence of EPS following treatment with lurasidone</p><p>compared to placebo.</p><p>&nbsp;</p><p><u>T</u><u>a</u><u>r</u><u>dive dyskinesia</u></p><p>Medicinal products with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical involuntary movements, predominantly of the tongue and/or face. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics, including lurasidone, should be considered.</p><p>&nbsp;</p><p><u>C</u><u>ardiovascular disorders/QT prolongation</u></p><p>Caution should be exercised when lurasidone is prescribed in patients with known cardiovascular disease or family history of QT prolongation, hypokalaemia, and in concomitant use with other</p><p>medicinal products thought to prolong the QT interval.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>Lurasidone should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.</p><p>&nbsp;</p><p><u>N</u><u>euroleptic malignant syndrome (NMS)</u></p><p>Neuroleptic Malignant Syndrome, characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels, has been reported to occur with antipsychotics including lurasidone. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. In this event, all antipsychotics, including lurasidone, should be discontinued.</p><p>&nbsp;</p><p><u>Elderly patients with dementia</u></p><p>Lurasidone has not been studied in elderly patients with dementia.</p><p>&nbsp;</p><p><u>O</u><u>v</u><u>erall mortality</u></p><p>In a meta-analysis of 17 controlled clinical trials, elderly patients with dementia treated with other atypical antipsychotics, including risperidone, aripiprazole, olanzapine, and quetiapine had an increased risk of mortality compared to placebo.</p><p>&nbsp;</p><p><u>C</u><u>erebrovascular accident</u></p><p>An approximately 3-fold increased risk of cerebrovascular adverse reactions has been seen in randomised placebo-controlled clinical trials in the dementia population with some atypical antipsychotics, including risperidone, aripiprazole and olanzapine. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. Lurasidone should be used with caution in elderly patients with dementia who have risk factors for stroke.</p><p>&nbsp;</p><p><u>V</u><u>enous thromboembolism</u></p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible</p><p>risk factors for VTE should be identified before and during treatment with lurasidone and preventive measures undertaken.</p><p>&nbsp;</p><p><u>H</u><u>y</u><u>perprolactinaemia</u></p><p>Lurasidone elevates prolactin levels due to antagonism of dopamine D2 receptors.</p><p>&nbsp;</p><p><u>Weight gain</u></p><p>Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.</p><p>&nbsp;</p><p><u>H</u><u>y</u><u>perglycaemia</u></p><p>Rare cases of glucose related adverse reactions, e.g. increase in blood glucose, have been reported in clinical trials with lurasidone. Appropriate clinical monitoring is advisable in diabetic patients and in patients with risk factors for the development of diabetes mellitus.</p><p>&nbsp;</p><p><u>O</u><u>rt</u><u>hostatic hypotension/syncope</u></p><p>Lurasidone may cause orthostatic hypotension, perhaps due to its &alpha;1-adrenergic receptor antagonism. Monitoring of orthostatic vital signs should be considered in patients who are vulnerable to hypotension.</p><p>&nbsp;</p><p><u>R</u><u>enal impairment</u></p><p>Dose adjustment is recommended for patients with moderate and severely impaired renal function and in patients with ESRD. Use in patients with ESRD has not been investigated and therefore lurasidone should not be used in patients with ESRD unless the potential benefits outweigh the potential risks. If used in patients with ESRD, clinical monitoring is advised (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>H</u><u>epatic impairment</u></p><p>Dose adjustment is recommended for patients with moderate and severely impaired hepatic function</p><p>(Child-Pugh Class B and C) (see sections 4.2 and 5.2). Caution is recommended in patients with severely impaired hepatic function.</p><p>&nbsp;</p><p><u>I</u><u>nteraction with Grapefruit juice</u></p><p>Grapefruit juice should be avoided during treatment with lurasidone (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions</u></p><p>&nbsp;</p><p>Given the primary central nervous system effects of lurasidone, lurasidone should be used with caution in combination with other centrally acting medicinal products and alcohol.</p><p>&nbsp;</p><p>Caution is advised when prescribing lurasidone with medicinal products known to prolong the QT interval, e.g. class IA antiarrhythmics (e.g. quinidine, disopyramide) and class III antiarrhythmics (e.g. amiodarone, sotalol), some antihistaminics, some other antipsychotics and some antimalarials (e.g. mefloquine).</p><p>&nbsp;</p><p><u>Pharmacokinetic interactions</u></p><p>&nbsp;</p><p>The concomitant administration of lurasidone and grapefruit juice has not been assessed. Grapefruit juice inhibits CYP 3A4 and may increase the serum concentration of lurasidone. Grapefruit juice should be avoided during treatment with lurasidone.</p><p>&nbsp;</p><p><u>Potential for other medicinal products to affect lurasidone</u></p><p>&nbsp;</p><p>Lurasidone and its active metabolite ID-14283 both contribute to the pharmacodynamic effect at the dopaminergic and serotonergic receptors. Lurasidone and its active metabolite ID-14283 are primarily metabolised by CYP3A4.</p><p>&nbsp;</p><p><em>C</em><em>Y</em><em>P3A4 inhibitors</em></p><p>Lurasidone is contraindicated with strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, cobicistat, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) (see section 4.3).</p><p>&nbsp;</p><p>Coadministration of lurasidone with the strong CYP3A4 inhibitor ketoconazole resulted in a 9- and</p><p>6-fold increase in exposure of lurasidone and its active metabolite ID-14283 respectively.</p><p>&nbsp;</p><p>Coadministration of lurasidone with medicinal products that moderately inhibit CYP3A4 (e.g. diltiazem, erythromycin, fluconazole verapamil) may increase exposure to lurasidone. Moderate CYP3A4 inhibitors are estimated to result in a 2-5 fold increase in exposure of CYP3A4 substrates.</p><p>&nbsp;</p><p>Coadministration of lurasidone with diltiazem (slow-release formulation), a moderate CYP3A4 inhibitor, resulted in a 2.2 and 2.4-fold increase in exposure of lurasidone and ID-14283 respectively (see section 4.2). The use of an immediate release formulation of diltiazem could result in a larger increase in lurasidone exposure.</p><p>&nbsp;</p><p><em>C</em><em>Y</em><em>P3A4 inducers</em></p><p>Lurasidone is contraindicated with strong CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, St John&rsquo;s wort (<em>Hypericum perforatum</em>)) (see section 4.3).</p><p>&nbsp;</p><p>Coadministration of lurasidone with the strong CYP3A4 inducer rifampicin resulted in a 6-fold decrease in exposure of lurasidone.</p><p>&nbsp;</p><p>Coadministration of lurasidone with mild (e.g. armodafinil, amprenavir, aprepitant, prednisone, rufinamide) or moderate (e.g. bosentan, efavirenz, etravirine, modafinil, nafcillin) inducers of CYP3A4 would be expected to give a &lt;2-fold reduction in lurasidone exposure during</p><p>co-administration and for up to 2 weeks after discontinuation of mild or moderate CYP3A4 inducers.</p><p>&nbsp;</p><p>When lurasidone is coadministered with mild or moderate CYP3A4 inducers, the efficacy of lurasidone needs to be carefully monitored and a dose adjustment may be needed.</p><p>&nbsp;</p><p><em>Transporters</em></p><p>Lurasidone is a substrate of P-gp and BCRP <em>in vitro </em>and the <em>in vivo </em>relevance of this is unclear. Coadministration of lurasidone with P-gp and BCRP inhibitors may increase exposure to lurasidone.</p><p>&nbsp;</p><p><u>Potential for lurasidone to affect other medicinal products</u></p><p>&nbsp;</p><p>Coadministration of lurasidone with midazolam, a sensitive CYP3A4 substrate, resulted in a &lt; 1.5-fold increase in midazolam exposure. Monitoring is recommended when lurasidone and CYP3A4</p><p>substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids [ergotamine, dihydroergotamine]) are coadministered.</p><p>&nbsp;</p><p>&nbsp;</p><p>Coadministration of lurasidone with digoxin (a P-gp substrate) did not increase the exposure to digoxin and only slightly increased Cmax (1.3 &ndash;fold) and therefore, it is considered that lurasidone can be coadministered with digoxin. Lurasidone is an <em>in vitro </em>inhibitor of the efflux transporter P-gp and the clinical relevance of intestinal P-gp inhibition cannot be excluded. Concomitant administration of the P-gp substrate dabigatran etexilate may result in increased dabigatran plasma concentrations.</p><p>&nbsp;</p><p>Lurasidone is an <em>in vitro </em>inhibitor of the efflux transporter BCRP and the clinical relevance of intestinal BCRP inhibition cannot be excluded. Concomitant administration of BCRP substrates may result in increases in the plasma concentrations of these substrates.</p><p>&nbsp;</p><p>Coadministration of lurasidone with lithium indicated that lithium had clinically negligible effects on the pharmacokinetics of lurasidone, therefore no dose adjustment of lurasidone is required when coadministered with lithium. Lurasidone does not impact concentrations of lithium.</p><p>&nbsp;</p><p>A clinical drug interaction study investigating the effect of coadministration of lurasidone on patients taking oral combination contraceptives including norgestimate and ethinyl estradiol, indicated that lurasidone had no clinically or statistically meaningful effects on the pharmacokinetics of the contraceptive or sex hormone binding globulin (SHBG) levels. Therefore, lurasidone can be coadministered with oral contraceptives.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of lurasidone in pregnant women. Animal studies are insufficient with respect to effects on pregnancy, embryonal/fetal development, parturition and postnatal development (see section 5.3). The potential risk for humans is unknown. Lurasidone should not be used during pregnancy unless clearly</p><p>necessary.</p><p>&nbsp;</p><p>Neonates exposed to antipsychotics (including lurasidone) during the third trimester are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p>&nbsp;</p><p><u>B</u><u>r</u><u>east-feeding</u></p><p>&nbsp;</p><p>Lurasidone was excreted in milk of rats during lactation (see section 5.3). It is not known whether lurasidone or its metabolites are excreted in human milk. Breast feeding in women receiving Latuda should be considered only if the potential benefit of treatment justifies the potential risk to the child.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Studies in animals have shown a number of effects on fertility, mainly related to prolactin increase, which are not considered to be relevant to human reproduction (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lurasidone has minor influence on the ability to drive and use machines. Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that lurasidone does not affect them adversely (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety of lurasidone has been evaluated at doses of 18.5 -148 mg in clinical studies in patients with schizophrenia treated for up to 52 weeks and in the post-marketing setting. The most common adverse drug reactions (ADRs) (&ge; 10%) were akathisia and somnolence, which were dose-related up to</p><p>111 mg daily.</p><p>&nbsp;</p><p><u>T</u><u>abulated summary of adverse reactions</u></p><p>&nbsp;</p><p>Adverse drug reactions (ADRs) based upon pooled data are shown by system, organ class and by preferred term are listed below. The incidence of ADRs reported in clinical trials is tabulated by frequency category. The following terms and frequencies are applied: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1000), very rare</p><p>(&lt;1 /10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong><u>T</u></strong><strong><u>able 1</u></strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>System Organ</strong></p><p><strong>Class</strong></p></td><td><p><strong>Very</strong></p><p><strong>Common</strong></p></td><td><strong>Common</strong></td><td><strong>Uncommon</strong></td><td><strong>Rare</strong></td><td><p><strong>Frequency not</strong></p><strong>known</strong></td></tr><tr><td><p>Infections and</p><p>infestations</p></td><td>&nbsp;</td><td>&nbsp;</td><td>Nasopharyngitis</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Blood and</p><p>lymphatic system disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>Eosinophilia</td><td><p>Leukopenia****</p><p>Neutropenia****</p><p>Anemia****</p></td></tr><tr><td><p>Immune system</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>Hypersensitivity#</td></tr><tr><td><p>Metabolism and</p><p>nutrition disorders</p></td><td>&nbsp;</td><td><p>Weight</p><p>increased</p></td><td><p>Decreased appetite</p><p>Blood glucose increased</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Psychiatric</p><p>disorders</p></td><td>&nbsp;</td><td><p>Insomnia</p><p>Agitation Anxiety Restlessness</p></td><td><p>Nightmare</p><p>Catatonia</p></td><td>&nbsp;</td><td><p>Suicidal</p><p>behaviour****</p><p>Panic attack****</p><p>Sleep disorder****</p></td></tr><tr><td><p>Nervous system</p><p>disorders</p></td><td><p>Akathisia</p><p>Somnolence*</p></td><td><p>Parkinsonism**</p><p>Dizziness Dystonia*** Dyskinesia</p></td><td><p>Lethargy</p><p>Dysarthria Tardive dyskinesia</p></td><td><p>Neuroleptic</p>malignant syndrome (NMS)</td><td>Convulsion****</td></tr><tr><td>Eye disorders</td><td>&nbsp;</td><td>&nbsp;</td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Blurred vision</p></td><td>&nbsp;</td></tr></tbody></table></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Ear and</p><p>labyrinth disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>Vertigo****</td></tr><tr><td><p>Cardiac</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Tachycardia</p></td><td>&nbsp;</td></tr></tbody></table></td><td>&nbsp;</td><td><p>Angina****</p>AV block first degree**** Bradycardia****</td></tr><tr><td><p>Vascular</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Hypertension</p><p>Hypotension</p><p>Orthostatic hypotension Hot flush Blood pressure increased</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Gastrointestinal</p><p>disorders</p></td><td>&nbsp;</td></tr></tbody></table></td><td>&nbsp;</td><td><p>Nausea</p><p>Vomiting Dyspepsia Salivary hypersecretion Dry mouth Upper abdominal pain Stomach discomfort</p></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Flatulence</p></td><td>&nbsp;</td></tr></tbody></table></td><td>&nbsp;</td><td><p>Diarrhoea****</p><p>Dysphagia****</p><p>Gastritis****</p></td></tr><tr><td><p>Hepatobiliary</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Alanine</p>aminotransferase increased</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>System Organ</strong></p><p><strong>Class</strong></p></td><td><p><strong>Very</strong></p><p><strong>Common</strong></p></td><td><strong>Common</strong></td><td><strong>Uncommon</strong></td><td><strong>Rare</strong></td><td><strong>Frequency not known</strong></td></tr><tr><td><p>Skin and</p>subcutaneous tissue disorders</td><td>&nbsp;</td><td>&nbsp;</td><td>Hyperhidrosis</td><td>&nbsp;</td><td><p>Rash****</p><p>Pruritus****</p><p>Angioedema****</p><p>Stevens-Johnson syndrome</p></td></tr><tr><td><p>Musculoskeletal</p>and connective tissue disorders</td><td>&nbsp;</td><td><p>Musculoskeletal</p><p>stiffness&nbsp;Blood creatine phosphokinase increase</p></td><td><p>Joint stiffness</p><p>Myalgia</p><p>Neck pain</p><p>Back pain</p></td><td>Rhabdomyolysis</td><td>&nbsp;</td></tr><tr><td><p>Renal and</p>urinary disorders</td><td>&nbsp;</td><td><p>Serum&nbsp;creatinine increased</p></td><td>Dysuria</td><td>&nbsp;</td><td>Renal failure****</td></tr><tr><td><p>Pregnancy,</p>puerperium and perinatal conditions</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Drug withdrawal syndrome neonatal&nbsp;(see 4.6)</p></td></tr><tr><td><p>Reproductive&nbsp;system and breast disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Blood prolactin&nbsp;increased</p></td><td>&nbsp;</td><td><p>Breast</p><p>enlargement****</p><p>Breast pain****</p><p>Galactorrhoea****</p><p>Erectile dysfunction****</p><p>Amenorrhoea**** Dysmenorrhoea****</p></td></tr><tr><td><p>General&nbsp;disorders and administration site conditions</p></td><td>&nbsp;</td><td>Fatigue</td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Gait disturbance</p></td></tr></tbody></table></td><td>&nbsp;</td><td><p>Sudden death attributable to underlying cardiovascular disease observed during the clinical</p>development programme****</td></tr></tbody></table><p>*Somnolence includes adverse reaction terms: hypersomnia, hypersomnolence, sedation, and somnolence</p><p>**Parkinsonism includes adverse reaction terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor</p><p>***Dystonia includes adverse reaction terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus.</p><p>****ADRs noted in Phase 2 and 3 controlled and uncontrolled studies; however, the incidence of occurrence for these</p><p>are too low to estimate frequencies.</p><p># Hypersensitivity may include symptoms such as throat swelling, tongue swelling, urticaria, or symptoms of angioedema, rash or pruritus (grouped under Skin and subcutaneous tissue disorders in Table 1).</p><p>&nbsp;</p><p><u>D</u><u>escription of selected adverse reactions</u></p><p>&nbsp;</p><p>Post marketing reports of clinically serious cases of skin and other hypersensitivity reactions have been reported in association with lurasidone treatment, including some reports of Stevens-Johnson syndrome.</p><p>&nbsp;</p><p><em>Events of interest to the class</em></p><p><em>Extrapyramidal symptoms (EPS)</em>: In the short-term placebo controlled studies, the incidence of reported events related to EPS, excluding akathisia and restlessness, was 13.5% for lurasidone-treated</p><p>subjects versus 5.8% for placebo-treated subjects. The incidence of akathisia for lurasidone-treated</p><p>subjects was 12.9% versus 3.0% for placebo-treated subjects.</p><p>&nbsp;</p><p><em>D</em><em>ystonia</em>: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of</p><p>&nbsp;</p><p>the neck muscles, sometimes progressing to tightness of the throat, difficulty swallowing, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity, higher potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</p><p>&nbsp;</p><p><em>Venous thromboembolism</em>: Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs -Frequency unknown.</p><p>&nbsp;</p><p><u>R</u><u>eporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in below:</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Management of overdose</u></p><p>&nbsp;</p><p>There is no specific antidote to lurasidone, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of QT-prolonging effects when administered in patients with an acute overdose of lurasidone. Similarly the alpha-blocking properties of bretylium might be additive to those of lurasidone, resulting in problematic hypotension.</p><p>&nbsp;</p><p>Hypotension and circulatory collapse should be treated with appropriate measures. Adrenaline and dopamine should not be used, or other sympathomimetics with beta agonist activity, since beta stimulation may worsen hypotension in the setting of lurasidone-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medicinal products should be administered.</p><p>&nbsp;</p><p>Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.</p><p>&nbsp;</p><p>The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: Psycholeptics, antipsychotics. ATC code: N05AE05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Lurasidone is a selective blocking agent of dopamine and monoamine effects. Lurasidone binds strongly to dopaminergic D2- and to serotonergic 5-HT2A and 5-HT7- receptors with high binding affinity of 0.994, 0.47 and 0.495 nM, respectively. It also blocks &alpha;2c-adrenergic receptors and</p><p>&alpha;2a-adrenergic receptors with a binding affinity of 10.8 and 40.7 nM respectively. Lurasidone also exhibits partial agonism at the 5HT-1A receptor with a binding affinity of 6.38 nM. Lurasidone does not bind to histaminergic or muscarinic receptors.</p><p>&nbsp;</p><p>The mechanism of action of the minor active metabolite of lurasidone ID-14283 is similar to that of lurasidone.</p><p>&nbsp;</p><p>Lurasidone doses ranging from 9 to 74 mg (10-80 mg lurasidone hydrochloride) administered to healthy subjects produced a dose-dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand, in the caudate, putamen and ventral striatum detected by positron emission tomography.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>In the main clinical efficacy studies, lurasidone was administered at doses of 37-148 mg lurasidone</p><p>(equivalent to 40-160 mg lurasidone hydrochloride).</p><p>&nbsp;</p><p><em>C</em><em>li</em><em>n</em><em>i</em><em>cal efficacy</em></p><p>The efficacy of lurasidone in the treatment of schizophrenia was demonstrated in five multi-centre, placebo-controlled, double-blind, 6-week trials in subjects who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia. Lurasidone doses, which varied across the five trials, ranged from 37 to 148 mg lurasidone (equivalent to 40-160 mg lurasidone hydrochloride) once daily. In the short-term trials, the primary efficacy endpoint was defined as the mean change from baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) total scores, a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganised thoughts, uncontrolled hostility/excitement, and anxiety/depression. Lurasidone demonstrated superior efficacy compared with placebo across Phase 3 studies (see Table</p><p>2). Lurasidone showed significant separation from placebo from as early as Day 4. Additionally, lurasidone was superior to placebo on the predefined secondary endpoint Clinical Global Impression &ndash;</p><p>Severity (CGI-S) scale. Efficacy was also confirmed in a secondary analysis of treatment response</p><p>(defined as &ge; 30% decrease from Baseline in PANSS total score).</p><p>&nbsp;</p><p><strong><u>T</u></strong><strong><u>able 2</u></strong></p><p><em>Schizophrenia Studies: Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total</em></p><p><em>Score - Change From Baseline to Week 6- MMRM for Studies D1050229, D1050231, and D1050233: Intent-to-Treat Analysis Set</em></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td rowspan="2" colspan="1"><strong>Study Statistic</strong></td><td rowspan="2" colspan="1"><strong>Placebo</strong></td><td rowspan="1" colspan="4"><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Lurasidone dose (b) (c)</strong></td><td rowspan="2" colspan="1"><strong>Active&nbsp;Control (a)</strong></td></tr><tr><td><strong>37 mg</strong></td><td><strong>74 mg</strong></td><td><strong>111 mg</strong></td><td><strong>148 mg</strong></td></tr><tr><td><p>Study D1050229&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>(9.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;--</p><p>Treatment Difference vs.&nbsp;&nbsp;&nbsp;placebo</p><p>Estimate (SE)</p><p>p-value&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td><p>N=124&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>96.8 (11.1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>-17.0 (1.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>--</p><p>--&nbsp;&nbsp; &nbsp;</p></td><td><p>N=121&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>96.5 (11.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>-19.2 (1.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>-2.1 (2.5)</p><p>0.591</p></td><td><p>N=118&nbsp;&nbsp;&nbsp;&nbsp;</p><p>96.0 (10.8)&nbsp;</p><p>-23.4 (1.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>-6.4 (2.5) &nbsp;</p><p>0.034&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;</p></td><td><p>&nbsp;N=123&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p>&nbsp;96.0(9.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;-20.5(1.8)&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;</p><p>-3.5 (2.5)</p><p>0.391&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p></td><td><p>--</p><p>--</p><p>--</p><p>&nbsp;</p><p>--</p><p>--</p></td><td><p>--</p><p>--</p><p>--</p><p>&nbsp;</p><p>--</p><p>--</p></td></tr><tr><td>Study D1050231</td><td>N=114</td><td>N=118</td><td>--&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>N=118</td><td>--</td><td><p>N=121</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td rowspan="2" colspan="1"><strong>Study Statistic</strong></td><td rowspan="2" colspan="1"><strong>Placebo</strong></td><td rowspan="1" colspan="4"><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Lurasidone dose (b) (c)</strong></td><td rowspan="2" colspan="1"><strong>Active&nbsp;Control (a)</strong></td></tr><tr><td><strong>37 mg</strong></td><td><strong>74 mg</strong></td><td><strong>111 mg</strong></td><td><strong>148 mg</strong></td></tr><tr><td><p>Baseline Mean(SD)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>LS Mean Change (SE) Treatment Difference vs. placebo</p><p>Estimate (SE)</p><p>p-value&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td><p>95.8 (10.8)</p><p>-16.0 (2.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p><p>--</p></td><td><p>96.6 (10.7)</p><p>-25.7 (2.0)</p><p>&nbsp;</p><p>&nbsp;</p><p>-9.7 (2.9)</p><p>0.002</p></td><td><p>--</p><p>--</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p><p>--&nbsp; &nbsp;&nbsp; &nbsp;</p></td><td><p>97.9 (11.3)</p><p>-23.6 (2.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>-7.5 (3.0)</p><p>0.022&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p></td><td><p>--</p><p>--</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p><p>--</p></td><td><p>96.3 (12.2)</p><p>-28.7 (1.9)</p><p>&nbsp;</p><p>&nbsp;</p><p>-12.6 (2.8)</p><p>&lt;0.001</p></td></tr><tr><td><p>Study D1050233</p><p>Baseline Mean (SD) LS Mean Change (SE)</p><p>Treatment Difference vs. placebo</p><p>Estimate (SE)</p><p>&nbsp;p-value</p><p>&nbsp;</p></td><td><p>N=120</p><p>96.6 (10.2)</p><p>-10.3 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p>&nbsp; &nbsp;--</td><td><p>--</p><p>--</p><p>--</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p>--</td><td><p>N=125</p><p>97.7 (9.7)</p><p>-22.2 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>-11.9 (2.6)</p>&lt;0.001&nbsp; &nbsp; &nbsp;&nbsp;</td><td><p>--</p><p>--</p><p>--</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p>&nbsp; &nbsp;--</td><td><p>N=121</p><p>97.9 (11.8)</p><p>-26.5 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>-16.2 (2.5)</p>&lt;0.001</td><td><p>N=116</p><p>97.7 (10.2)</p><p>-27.8 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>-17.5 (2.6)</p>&lt;0.001</td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>(a) Olanzapine 15 mg in Study D1050231, quetiapine extended-release (XR) 600 mg in Study D1050233.</p><p>N is number of subjects per model estimate.</p><p>(b) p-values for lurasidone vs. placebo were adjusted for multiple comparisons. P-values for olanzapine and quetiapine XR vs. placebo were unadjusted.</p><p>(c) Lurasidone doses of 37, 74, 111 and 148 mg are equivalent to 40, 80, 120 and 160 mg amounts of lurasidone hydrochloride.</p><p>&nbsp;</p><p>In the short-term studies there was no consistent dose-response correlation observed.</p><p>&nbsp;</p><p>Long-term maintenance efficacy of lurasidone (37 to 148 mg lurasidone once daily (equivalent to</p><p>40 -160 mg lurasidone hydrochloride)) was demonstrated in a 12 month non-inferiority trial with quetiapine extended release (XR) (200 to 800 mg once daily). Lurasidone was non-inferior to</p><p>quetiapine XR in time to relapse of schizophrenia. Lurasidone had a small increase from baseline to Month 12 in body weight and body mass index (Mean (SD): 0.73 (3.36) kg and 0.28 (1.17) kg/m2, respectively) compared to quetiapine XR (1.23 (4.56) kg and 0.45 (1.63) kg/m2, respectively). Overall, lurasidone had a negligible effect on weight and other metabolic parameters including total</p><p>cholesterol, triglycerides, and glucose levels.</p><p>&nbsp;</p><p>In a long-term safety study clinically stable patients were treated using 37 &ndash; 111 mg lurasidone (equivalent to 40 &ndash; 120 mg lurasidone hydrochloride) or risperidone 2 &ndash; 6 mg. In that study the rate of relapse over a 12-month period was 20% for lurasidone and 16% for risperidone. This difference neared, but did not reach, statistical significance.</p><p>&nbsp;</p><p>In a long-term trial designed to assess the maintenance of effect, lurasidone was more effective than placebo in maintaining symptom control and delaying relapse of schizophrenia. After having been treated for an acute episode and stabilized for a minimum of 12 weeks with lurasidone, patients were then randomised in a double-blind manner to either continue on lurasidone or on placebo until they experienced a relapse in schizophrenia symptoms. In the primary analysis of time to relapse in which patients that withdrew without relapse were censored at the time of withdrawal, patients on lurasidone showed a significantly longer time to relapse compared with patients on placebo (p=0.039). The Kaplan-Meier estimates of the probability of relapse at Week 28 were 42.2% for lurasidone and 51.2% for placebo. The probability of all-cause discontinuation at Week 28 were 58.2% for lurasidone and</p><p>69.9% for placebo (p=0.072).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with lurasidone in one or more subsets of the paediatric population in schizophrenia (see section 4.2 for information on paediatric use).</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.2&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</strong></p><p>&nbsp;</p><p><u>A</u><u>bsorption</u></p><p>&nbsp;</p><p>Lurasidone reaches peak serum concentrations in approximately 1-3 hours.</p><p>&nbsp;</p><p>In a food effect study, lurasidone mean Cmax and AUC increased approximately by 2-3-times and</p><p>1.5-2-times, respectively, when administered with food compared to the levels observed under fasting</p><p>conditions. <u>Distribution</u></p><p>Following administration of 37 mg of lurasidone (equivalent to 40 mg lurasidone hydrochloride), the mean approximate apparent volume of distribution was 6000 L. Lurasidone is highly bound (~99%) to serum proteins.</p><p>&nbsp;</p><p><u>B</u><u>i</u><u>otransformation</u></p><p>&nbsp;</p><p>Lurasidone is metabolised mainly via CYP3A4. The major biotransformation pathways are oxidative</p><p>N-dealkylation, hydroxylation of norbornane ring, and S-oxidation.</p><p>&nbsp;</p><p>Lurasidone is metabolised into two active metabolites (ID-14283 and ID-14326) and two non-active metabolites (ID-20219 and ID-20220). Lurasidone and its metabolites ID-14283, ID-14326, ID-20219 and ID-20220 correspond to approximately 11.4, 4.1, 0.4, 24 and 11% respectively, of serum radioactivity respectively.</p><p>&nbsp;</p><p>CYP3A4 is the major enzyme responsible for metabolism of the active metabolite ID-14283. Lurasidone and its active metabolite ID-14283 both contribute to the pharmacodynamic effect at the dopaminergic and serotonergic receptors.</p><p>&nbsp;</p><p>Based on <em>in vitro </em>studies lurasidone is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes.</p><p>&nbsp;</p><p><em>I</em><em>n vitro, </em>lurasidone demonstrated no direct, or weak inhibition (direct or time-dependent) (IC50&gt;5.9 &mu;M) of the enzymes cytochrome P450 (CYP)1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. Based on this data, lurasidone is not expected to affect the</p><p>pharmacokinetics of medicinal products that are substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. For administration of medicinal products that are substrates of</p><p>CYP3A4 with a narrow therapeutic range, see section 4.5.</p><p>&nbsp;</p><p>Lurasidone is an <em>in vitro </em>substrate of the efflux transporters P-gp and BCRP. Lurasidone is not subject to active uptake transport by OATP1B1 or OATP1B3.</p><p>&nbsp;</p><p>Lurasidone is an inhibitor of P-gp, BCRP and OCT1 <em>in vitro </em>(see section 4.5). Lurasidone is not expected to have a clinically relevant inhibitory potential on transporters OATP1B1, OATP1B3, OCT2, OAT1, OAT3, MATE1, MATE2K or BSEP based on <em>i</em><em>n vitro </em>data.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Following administration of lurasidone, the elimination half-life was 20-40 hours. Following oral administration of a radiolabelled dose, approximately 67% dose was recovered in faeces and 19% in urine. Urine comprised mostly of a number of metabolites with minimal renal excretion of parent compound.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>The pharmacokinetics of lurasidone is dose-proportional within a total daily dose range of 18.5 mg to</p><p>148 mg (equivalent to 20 to 160 mg lurasidone hydrochloride). Steady-state concentrations of lurasidone are reached within 7 days of starting lurasidone.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups:</u></p><p>&nbsp;</p><p><em>Elderly people</em></p><p>Limited data have been collected in healthy subjects &ge; 65 years. Of the data collected, similar exposure was obtained compared with subjects &lt; 65 years. However, an increase in exposure in elderly subjects may be expected for patients if they have impaired renal or hepatic function.</p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>The serum concentrations of lurasidone are increased in healthy subjects with Child-Pugh Class A, B</p><p>and C hepatic impairment with an increased exposure of 1.5-, 1.7- and 3-fold respectively.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>The serum concentrations of lurasidone are increased in healthy subjects with mild, moderate and severe renal impairment with an increased exposure of 1.5, 1.9 and 2.0-fold respectively. Subjects</p><p>with ESRD (CrCl&lt;15 ml/min) have not been investigated.</p><p>&nbsp;</p><p><em>G</em><em>ender</em></p><p>There were no clinically relevant differences between genders in the pharmacokinetics of lurasidone in a population pharmacokinetic analysis in patients with schizophrenia.</p><p>&nbsp;</p><p><em>Race</em></p><p>There were no clinically relevant differences in the pharmacokinetics of lurasidone in a population pharmacokinetic analysis in patients with schizophrenia. It was noted that Asian subjects had 1.5 fold increased exposure to lurasidone compared to Caucasian subjects.</p><p>&nbsp;</p><p><em>Smoking</em></p><p>Based on <em>in vitro </em>studies utilising human liver enzymes, lurasidone is not a substrate for CYP1A2;</p><p>smoking should, therefore, not have an effect on the pharmacokinetics of lurasidone.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of lurasidone in paediatric patients was investigated in 49 children aged</p><p>6-12 years and 56 adolescents aged 13-17 years. Lurasidone was administered as lurasidone hydrochloride at daily doses of either 20, 40, 80, 120 mg (6-17 years) or 160 mg (10-17 years only) for</p><p>7 days. There was no clear correlation between obtained plasma exposure and age or body weight. The pharmacokinetics of lurasidone in paediatric patients aged 6&ndash;17 years was generally comparable to</p><p>those observed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3&nbsp;&nbsp;&nbsp; Preclinical safety data</strong></p><p>&nbsp;</p><p>Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Major findings in repeat-dose toxicity studies of lurasidone were centrally-mediated endocrine changes resulting from serum prolactin elevations in rats, dogs and monkeys. High serum prolactin levels in long-term repeat-dose studies in female rats were associated with effects on bones, adrenal glands, and</p><p>reproductive tissues. In a long-term dog repeat-dose study, high serum prolactin levels were associated with effects on male and female reproductive tissues.</p><p>&nbsp;</p><p>In rats, lurasidone had no effect on male and female reproduction at oral doses of 150 and</p><p>0.1 mg/kg/day lurasidone hydrochloride, respectively, or on early embryonic development at an oral dose of 15 mg/kg/day lurasidone hydrochloride.</p><p>&nbsp;</p><p>A fertility study in female rats resulted in prolonged estrous cycle and delayed copulation at</p><p>&ge;1.5 mg/kg/day lurasidone hydrochloride, whilst the copulation and fertility indices, and the numbers of corpora lutea, implantations and live fetuses were decreased at 150 mg/kg/day lurasidone hydrochloride. These effects were due to the hyperprolactinemia following lurasidone treatment, affecting the estrous cycle and copulatory behaviour as well as the maintenance of corpus luteum of</p><p>&nbsp;</p><p>the female rats, resulting in a decrease in implantation and the number of live foetuses. These prolactin-related effects are not considered to be relevant to human reproduction.</p><p>&nbsp;</p><p>A single dose of 10 mg/kg lurasidone hydrochloride to pregnant rats resulted in fetal exposure. In a dose range finding study in pregnant rats, 150 mg/kg/day lurasidone hydrochloride caused fetal growth retardation without signs of teratogenicity. Lurasidone was not teratogenic in rats or rabbits at an exposure similar to or below the maximum recommended human dose (148 mg lurasidone equivalent to 160 mg lurasidone hydrochloride).</p><p>&nbsp;</p><p>Lurasidone was excreted in milk of rats during lactation.</p><p>&nbsp;</p><p>Lurasidone was not genotoxic in a battery of tests. Mammary gland and/or pituitary gland tumours were observed in the mouse and rat carcinogenicity studies and are most likely due to the increased blood prolactin levels. These findings are common in rodents treated with antipsychotic medicinal products with dopamine D2 blocking activity and are considered to be rodent-specific.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>C</u><u>ore</u></p><p>Mannitol (E 421) Starch, pregelatinised</p><p>Croscarmellose sodium (E468)</p><p>Hypromellose 2910 (E 464) Magnesium stearate (E 470b)</p><p>&nbsp;</p><p><u>T</u><u>ablet coating</u> Hypromellose 2910 (E 464) Titanium dioxide (E 171) Macrogol 8000</p><p>Carnauba wax (E 903)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.5&nbsp;&nbsp;&nbsp; Nature and contents of container</strong></p><p>&nbsp;</p><p>Cartons contain 28 tablets in aluminium/aluminium perforated unit dose blisters (2 blister strips, each containing 14 film coated tablets).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sunovion Pharmaceuticals Europe Ltd. First Floor
Southside
97-105 Victoria Street
London SW1E 6QT United Kingdom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                {03/2016}
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>